MONTREAL, QUEBEC--(Marketwire - Sept. 5, 2008) -- Adaltis Inc. (TSX:ADS) "Adaltis"), an international in vitro diagnostic company, today announced that it has closed the first tranche (the "First Tranche") of its previously announced private placement with Clarity China Partners, L.P. and certain of its affiliates (collectively, "Clarity China") and FMRC Family Trust, a trust of which Dr. Francesco Bellini is a beneficiary ("FMRC"). Adaltis has issued 10% senior secured convertible notes due in 2013 (the "Notes") with an issue price of Cdn.$16 million (Cdn.$15 million from Clarity China and Cdn.$1 million from FMRC) and a stated redemption price at maturity of Cdn.$16.6 million, reflecting additional consideration to be paid to Clarity China for its participation in the financing. The second tranche (the "Second Tranche") of Cdn.$4 million will be provided to Adaltis by Clarity China within ninety (90) days from the date hereof. The Notes will bear interest at 10% per annum and will mature five years from the date of issuance.
